Otaplimastat

小分子

奥他司他

Otaplimastat

O650865-5mg

5mg

≥98%

-20°C储存

超低温冰袋运输

Otaplimastat (SP-8203), a matrix metalloproteinase (MMP) inhibitor, blocks N-methyl-D-aspartate (NMDA) receptor -mediated excitotoxicity in a competitive manner. Otaplimastat also exhibits anti-oxidant activity. Otaplimastat can be used for the research of brain ischemic injury In Vitro Otaplimastat (87.5-350 μM; 20 min) protects neuronal cells against NMDA-induced cell death in a competitive manner. Otaplimastat (350 μM) inhibits Ca 2+ influx following activation of NMDA receptors in primary cultured neuron. Otaplimastat (2-200 μM; pretreated for 4 h) significantly suppresses H 2 O 2 -induced cell death and reactive oxygen species production. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Otaplimastat (10-20 mg/kg; i.p. 30 min before occlusion and 1 h after reperfusion) prevents ischemic neuronal death in the occlusion model of MCA . Otaplimastat (5-10 mg/kg; i.p. daily for 10 days) attenuates impairment of stroke-induced motor function. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Wistar rats (280-310 g, 9 weeks) were induced transient middle cerebral artery (MCA) occlusion Dosage: 10, 20 mg/kg Administration: I.p. before 30 min and after an hour of the MCA-occlusion operation Result: Significantly reduced infarct volume. Improved spatial learning and memory impairments. Form:Solid IC50& Target:MMP NMDA

奥他匹马司他（SP-8203）是一种基质金属蛋白酶（MMP）抑制剂，能以竞争性方式阻断 N-甲基-D-天冬氨酸（NMDA）受体介导的兴奋毒性。奥他拉马司他还具有抗氧化活性。奥他氨马司他可用于研究

1176758-04-5

C28H34N6O5

534.61 g/mol

44229378

CC(=O)N(CCCCNCCCN1C(=O)C2=CC=CC=C2NC1=O)CCCN3C(=O)C4=CC=CC=C4NC3=O

CC(=O)N(CCCCNCCCN1C(=O)C2=CC=CC=C2NC1=O)CCCN3C(=O)C4=CC=CC=C4NC3=O

44229378

DMSO : 100 mg/mL (187.05 mM; Need ultrasonic)

3

6

13

534.259 Da

534.259 Da

131.000 Ų

39

0

913

0

1

1.5